241 related articles for article (PubMed ID: 27164061)
1. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
Damlaj M; Alkhateeb HB; Hefazi M; Partain DK; Hashmi S; Gastineau DA; Al-Kali A; Wolf RC; Gangat N; Litzow MR; Hogan WJ; Patnaik MM
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1431-1439. PubMed ID: 27164061
[TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
3. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
4. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Kawamura K; Kako S; Mizuta S; Ishiyama K; Aoki J; Yano S; Fukuda T; Uchida N; Ozawa Y; Eto T; Iwato K; Kanamori H; Kahata K; Kondo T; Sawa M; Ichinohe T; Atsuta Y; Kanda Y
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2079-2087. PubMed ID: 28890406
[TBL] [Abstract][Full Text] [Related]
6. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Robin M; Porcher R; Wolschke C; Sicre de Fontbrune F; Alchalby H; Christopeit M; Cassinat B; Zabelina T; Peffault de Latour R; Ayuk F; Socié G; Kröger N
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1206-1211. PubMed ID: 26970380
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.
Sibai H; Falcone U; Deotare U; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Lipton JH; Seftel MD; Messner HA; Kim DDH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2270-2275. PubMed ID: 27596129
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
9. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.
Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Ayala E; Perez L; Fernandez H; Fancher K; Tate C; Shaw LM; Milone MC; Gardiner JA; Miller S; Anasetti C
Bone Marrow Transplant; 2011 Nov; 46(11):1418-25. PubMed ID: 21132026
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
De La Serna J; Sanz J; Bermúdez A; Cabrero M; Serrano D; Vallejo C; Gómez V; Moraleda JM; Perez SG; Caballero MD; Conde E; Lahuerta JJ; Sanz G
Bone Marrow Transplant; 2016 Jul; 51(7):961-6. PubMed ID: 26950372
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
14. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.
Jain T; Alahdab F; Firwana B; Sonbol MB; Almader-Douglas D; Palmer J
Biol Blood Marrow Transplant; 2019 Apr; 25(4):728-733. PubMed ID: 30471339
[TBL] [Abstract][Full Text] [Related]
15. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock C; Jackson A; Loke J; Siddique S; Hodgkinson A; Mason J; Andrew G; Nagra S; Malladi R; Peniket A; Gilleece M; Salim R; Tholouli E; Potter V; Crawley C; Wheatley K; Protheroe R; Vyas P; Hunter A; Parker A; Wilson K; Pavlu J; Byrne J; Dillon R; Khan N; McCarthy N; Freeman SD
J Clin Oncol; 2021 Mar; 39(7):768-778. PubMed ID: 33373276
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.
Yamamoto W; Andou T; Itabashi M; Koyama S; Ishii Y; Numata A; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S
Intern Med; 2016; 55(13):1721-7. PubMed ID: 27374671
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
[TBL] [Abstract][Full Text] [Related]
18. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A
Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135
[TBL] [Abstract][Full Text] [Related]
19. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Yamada Y; Ikegawa S; Najima Y; Atsuta Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Kaito S; Nagata R; Noguchi Y; Marumo A; Mukae J; Inamoto K; Toya T; Igarashi A; Kobayashi T; Sakamaki H; Ohashi K; Doki N
Int J Hematol; 2022 Feb; 115(2):244-254. PubMed ID: 34652634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
